Cutaneous T-Cell Lymphoma (CTCL): Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of extranodal non-Hodgkin lymphomas derived from skin-homing T-lymphocytes, classified under the 2018 WHO-EORTC system for primary cutaneous lymphomas. Mycosis fungoides (MF) is the most common subtype, accounting for approximately 50–70% of all CTCL; Sezary syndrome (SS) is the aggressive leukemic variant representing 5%. Together they comprise approximately 75% of all primary cutaneous lymphomas. The estimated US incidence is 6–7 cases per million per year, with a median age at diagnosis of 57 years and a male-to-female ratio of 2:1. Early-stage MF behaves as a chronic, often lifelong skin disease, while advanced-stage disease and Sezary syndrome have substantially reduced survival. The disease runs through characteristic clinical stages: patch, plaque, and tumor, with systemic spread to lymph nodes, blood, and visceral organs in advanced cases.

The etiology of CTCL remains incompletely understood, though it is thought to arise from chronic clonal expansion of skin-resident CD4+ T-cells. Proposed mechanisms include chronic antigenic stimulation by bacterial superantigens (particularly Staphylococcus aureus), prior viral exposure (HTLV-1 in endemic regions such as Japan and the Caribbean), occupational chemical exposures (solvents, pesticides), and acquired chromosomal instability. Recurrent somatic mutations in genes regulating T-cell receptor signaling (including PLCG1, CARD11, JAK3, and DNMT3A) have been identified. Dark-skinned populations have a 2-fold higher incidence than white populations. No single causative agent or hereditary risk factor has been definitively confirmed, and most cases arise sporadically without identifiable trigger.

Mycosis fungoides progresses through clinical stages: the patch stage presents as flat, irregularly shaped erythematous lesions resembling eczema or psoriasis, often on sun-protected skin (buttocks, trunk). The plaque stage shows indurated raised plaques with defined borders, while the tumor stage features nodular or ulcerated cutaneous tumors. Pruritus (itching) is often severe and persistent, profoundly impairing quality of life. Sezary syndrome causes erythroderma (diffuse erythema covering over 80% of body surface area), alopecia, nail dystrophy, palmoplantar hyperkeratosis, severe pruritus, generalized lymphadenopathy, and circulating malignant Sezary T-cells. Systemic spread to lymph nodes and viscera occurs in advanced disease stages. Symptoms of Cutaneous T-Cell Lymphoma (CTCL): Causes, Symptoms, Diagnosis and Treatment can range from mild to severe and may develop gradually or appear suddenly. Common presentations include pain, inflammation, or functional impairment related to the affected system. Symptoms may fluctuate over time with periods of remission and exacerbation. Consult a healthcare provider if symptoms persist or worsen, as early diagnosis improves outcomes.

Diagnosis requires skin biopsy with histopathology demonstrating epidermotropic CD4+/CD8− T-cell infiltrate, often with Pautrier microabscesses (collections of lymphocytes within the epidermis). T-cell receptor (TCR) gene rearrangement by PCR confirms clonal T-cell expansion. Immunohistochemistry defines CD3, CD4, CD7, CD26, and CD30 expression patterns. Flow cytometry of peripheral blood detects circulating Sezary cells (CD4+/CD7− or CD4+/CD26− phenotype) and is essential for staging leukemic disease. CT chest, abdomen, and pelvis evaluate lymph node and visceral involvement. PET-CT adds functional staging information for lymphadenopathy. TNMB staging (ISCLC system) classifies disease from T1 (patches/plaques <10% BSA) through T4 (erythroderma), with blood (B0–B2) and node involvement assessed separately.

Treatment is stage-directed. Early-stage MF (IA–IIA): skin-directed therapies are preferred, including topical high-potency corticosteroids (class I–II), topical mechlorethamine (Valchlor gel), topical carmustine, PUVA phototherapy (psoralen plus UVA, ORR 70–90%), narrowband UVB for thin patches, and local radiation. Total skin electron beam therapy (TSEB, 12–36 Gy) treats extensive skin involvement. Advanced MF and Sezary syndrome: systemic agents include oral bexarotene (RAR agonist), vorinostat or romidepsin (HDAC inhibitors), pralatrexate, and alemtuzumab. Mogamulizumab (anti-CCR4 monoclonal antibody) is approved for relapsed/refractory MF and SS based on the MAVORIC trial (superior PFS: 7.7 vs 3.1 months versus vorinostat). Allogeneic SCT is potentially curative for eligible young patients with advanced disease. Pembrolizumab and brentuximab vedotin (CD30+ tumors) are additional options in later lines.

Prognosis varies widely by stage. Stage IA MF has a disease-specific 10-year survival exceeding 97%; most patients with early-stage disease live near-normal lifespans. Stage IB–IIA: 10-year survival exceeds 80%, with many patients experiencing indolent disease for decades. Stage IIB tumor-stage MF carries a median survival of 4–5 years. Stage IV disease (extensive lymph node or visceral involvement) and Sezary syndrome carry a median survival of 1–3 years. Allogeneic SCT in eligible young patients with advanced-stage disease offers the best chance of durable disease control, with 5-year DFS of approximately 30–40%. The prognosis for Cutaneous T-Cell Lymphoma (CTCL): Causes, Symptoms, Diagnosis and Treatment varies depending on severity at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients achieve good outcomes and maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.

No established preventive strategies exist for CTCL, as the cause remains largely unknown. Patients with a history of atopic dermatitis or other chronic skin inflammatory conditions, who develop persistent, treatment-resistant skin lesions, should be evaluated by a dermatologist experienced in lymphoma. Prompt skin biopsy of suspicious plaques or patches — particularly those failing standard eczema or psoriasis therapies — enables earlier diagnosis and stage-appropriate treatment. Avoiding immunosuppressive agents unnecessarily in patients with known or suspected CTCL is important. UV exposure, while used therapeutically (PUVA, nbUVB) in controlled settings, should be managed carefully. Patients with confirmed CTCL benefit from lifelong surveillance by a multidisciplinary team including dermatology, hematology, and radiation oncology.

Consult a dermatologist promptly if you have persistent skin lesions — patches, plaques, or rashes — that have not responded to standard eczema or psoriasis treatments after 4–8 weeks. Any non-healing skin ulcer, rapidly enlarging cutaneous nodule, or new skin tumor requires urgent evaluation. Seek immediate care for sudden onset of widespread redness covering most of the body (erythroderma), which may indicate Sezary syndrome. Symptoms of lymph node swelling (firm, painless lumps in the neck, armpits, or groin), unexplained fever, drenching night sweats, or unintentional weight loss of more than 10% body weight within 6 months require urgent hematology-oncology referral. Patients with known CTCL who develop new lesions in a new distribution, worsening pruritus, or any systemic symptoms should contact their specialist without delay.